Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2005 Mar;115(3):586-8.
doi: 10.1172/JCI24518.

Illuminating the role of type I IFNs in colitis

Stefan Wirtz  1 , Markus F Neurath
Affiliations
Comment

Illuminating the role of type I IFNs in colitis

Stefan Wirtz et al. J Clin Invest. 2005 Mar.

Abstract

Recently, type I interferons IFN-alpha and IFN-beta (IFN-alpha/beta) have been evaluated in pilot clinical trials for the treatment of active ulcerative colitis. However, the underlying mechanisms that may contribute to a potential therapeutic effect are incompletely understood. A new study in this issue demonstrates a protective role for IFN-alpha/beta, induced by activation of a Toll-like receptor 9-dependent pathway, in a rodent model of experimental colitis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Hypothetical model for a regulatory role of type I IFNs in the gut. Intestinal bacteria entering the mucosa after epithelial damage or exogenous administration of CpG ODNs are recognized by mucosal plasmacytoid dendritic cells (pDCs) via TLR9. Stimulated pDCs produce IFN-α/β, which promote epithelial regeneration or generation of regulatory T cell subsets (e.g., T regulatory 1 cells; Tr1).
See this image and copyright information in PMC

Comment on

References

    1. Targan SR, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N. Engl. J. Med. 1997;337:1029–1035. - PubMed
    1. Mannon PJ, et al. Anti-interleukin-12 antibody for active Crohn’s disease. N. Engl. J. Med. 2004;351:2069–2079. - PubMed
    1. Madsen SM, et al. An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis. Am. J. Gastroenterol. 2001;96:1807–1815. - PubMed
    1. Nikolaus S, et al. Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut. 2003;52:1286–1290. - PMC - PubMed
    1. Bogdan C, Mattner J, Schleicher U. The role of type I interferons in non-viral infections. Immunol. Rev. 2004;202:33–48. - PubMed